Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

LIU Hongchuan, JIN Yongsheng, CHEN Haisheng. Research progress of structural modification of oridonin[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 114-115,134. doi: 10.3969/j.issn.1006-0111.2016.02.005
Citation: LIU Hongchuan, JIN Yongsheng, CHEN Haisheng. Research progress of structural modification of oridonin[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 114-115,134. doi: 10.3969/j.issn.1006-0111.2016.02.005

Research progress of structural modification of oridonin

doi: 10.3969/j.issn.1006-0111.2016.02.005
  • Received Date: 2014-07-24
  • Rev Recd Date: 2014-12-09
  • Oridonin is an en-kaurene diterpenoids compound which was found to have effect on tumor in vitro. But the clinical application has been limited because of poor water solubility, low bioavailability and oral absorption. Many scholars conducted a large number of structure modification researches of oridonin to search for new diterpenes with higher bio-activities and better bio-availabilities, and to develop new antitumor drugs. In this paper, studies on this aspect of oridonin were reviewed.
  • [1] 中国科学院.中国植物志[M].北京:科学出版社,2005,66:457-458.
    [2] Zhu Y, Xie L, Chen G,et al. Effects of oridonin on prolifera-tion of HT29 human colon carcinoma cell lines both in vitro and in vivo in mice[J]. Pharmazie, 2007,62(6):439-444.
    [3] Guo Y, Shan Q, Gong Y P,et al. Anti-leukemia effect of oridonin on Ph+ acute lymphoblastic leukemia cell SUP-B15[J]. Zhonghua Xueyexue Zazhi,2012,33(6):439-443.
    [4] Li X, Guo J M, Xu K, et al. Inhibitory mechanism of down-regulation expression of pp-GalNAc-T14 by oridonin on human renal carcinoma cells in vitro[J].Fudan Xuebao, Yixueban. 2012, 39(3):273-276, 292.
    [5] Xu W,Sun J Z,et al. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma[J]. Acta Pharmacol Sin,2006,27(12):1642-1646.
    [6] Nagao Y, Fujita E,Kohno T,et al. An efficient method for selective acetylation of alcoholic hydroxyl groups. Chem Pharm Bull[J]. 1981, 29:3202-3207.
    [7] Xu J Y, Yang J Y, RanQ,et al. Synthesis and biological evaluation of novel 1-O-and 14-O-derivatives of oridonin as potential anticancer drug candidates[J]. Bioorg Med Chem Lett, 2008,18:4741-4744.
    [8] Wang L, Ran Q, Li D H,et al. Synthesis and anti-tumor activity of 14-O-Derivatives of natural oridonin[J]. Chin J Nat Med,2011, 9(3):194-198.
    [9] 徐星星,刘舒畅,王琴荣,等. 冬凌草甲素衍生物的合成及其抗白血病活性研究[J]. 中国药物化学杂志,2011, 21(1):1-6.
    [10] 阎学斌,雷萌,张建业,等.冬凌草甲素葡萄糖苷的合成[J]. 有机化学, 2005, 25(2):222-224.
    [11] 阎学斌,张建业,可钰, 等.冬凌草甲素芳胺类衍生物的合成及其抗肿瘤活性[J]. 郑州大学学报(医学版), 2007, 42(1):39-41.
    [12] 南发俊,张仰明,刘桦南,等.一种对映-贝壳杉烷型二萜及其衍生物和制备方法:中国,102584760[P]. 2012-07-18.
    [13] 徐进宜,王磊,张奕华,等. 具有抗肿瘤活性的ent-6,7-开环贝壳杉烯型冬凌草甲素衍生物、其制备方法及用途:中国,102002051B[P].2013-06-19.
    [14] 徐进宜,李达翃,蔡浩,等. 具有抗肿瘤活性的冬凌草甲素及6,7-开环冬凌草甲素含氟衍生物、制备方法及用途:中国,102295649A[P].2011-12-28.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(3757) PDF downloads(36) Cited by()

Related
Proportional views

Research progress of structural modification of oridonin

doi: 10.3969/j.issn.1006-0111.2016.02.005

Abstract: Oridonin is an en-kaurene diterpenoids compound which was found to have effect on tumor in vitro. But the clinical application has been limited because of poor water solubility, low bioavailability and oral absorption. Many scholars conducted a large number of structure modification researches of oridonin to search for new diterpenes with higher bio-activities and better bio-availabilities, and to develop new antitumor drugs. In this paper, studies on this aspect of oridonin were reviewed.

LIU Hongchuan, JIN Yongsheng, CHEN Haisheng. Research progress of structural modification of oridonin[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 114-115,134. doi: 10.3969/j.issn.1006-0111.2016.02.005
Citation: LIU Hongchuan, JIN Yongsheng, CHEN Haisheng. Research progress of structural modification of oridonin[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 114-115,134. doi: 10.3969/j.issn.1006-0111.2016.02.005
Reference (14)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return